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Abstract
Background:  In perfused hearts, high calcium-induced inotropy results in less developed pressure
relative to myocardial oxygen consumption compared to the β -adrenergic agonist dobutamine.
Calcium handling is an important determinant of myocardial oxygen consumption. Therefore, we
hypothesized that this phenomenon was due to reduced myofilament responsiveness to calcium,
related to protein kinase C activation.
Results:  Developed pressure was significantly higher with dobutamine compared to high perfusate
calcium of 3.5 mM (73 ± 10 vs 63 ± 10 mmHg, p < 0.05), though peak systolic intracellular calcium
was not significantly different, suggesting reduced myofilament responsiveness to intracellular
calcium with high perfusate calcium. The ratio of developed pressure to myocardial oxygen
consumption, an index of economy of contraction, was significantly increased with dobutamine
compared to high perfusate calcium (1.35 ± 0.15 vs 1.15 ± 0.15 mmHg/µmoles/min/g dry wt, p <
0.05), suggesting energetic inefficiency with high perfusate calcium. The specific protein kinase C
inhibitor, chelerythrine, significantly attenuated the expected increase in developed pressure when
increasing perfusate calcium from 2.5 to 3.5 mM (3.5 mM: 64 ± 8 vs 3.5 mM + chelerythrine 55 ±
5 mmHg, p < 0.05), though had no effects on dobutamine, or lower levels of perfusate calcium (1.5
to 2.5 mM).
Conclusions:  By measuring intracellular calcium, developed pressures and myocardial oxygen
consumption in perfused mouse hearts, these results demonstrate that high perfusate calcium
positive inotropy results in reduced myofilament responsiveness to intracellular calcium.This is
compared to dobutamine, which is associated with energetic inefficiency and evidence of protein
kinase C activation.
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Background
During positive inotropy there is an increase in ATP uti-
lization and thus myocardial oxygen consumption relat-
ed to increased cross-bridge cycling and calcium
handling [1]. Heat measurements of isolated heart mus-
cle have assigned approximately 50% of total energy con-
sumption to cross-bridge cycling and 20% to calcium
cycling [2]. However, recently, studies in both isolated
hearts and myocytes [3,4], examining the energetic ef-
fects of increasing inotropy with the calcium sensitizing
agent EMD 57033 have suggested that the energetic cost
associated with increasing inotropy is largely related to
calcium cycling. In these studies EMD 57033 resulted in
only small increases in myocardial oxygen consumption
and this was felt related to the ability of EMD 57033 to
increase inotropy without increasing calcium cycling
(though intracellular calcium was not directly meas-
ured). Consistent with this Brandes et al [5] have studied
the contribution of mechanical work and calcium cycling
to total mitochondrial ATP hydrolysis as measured by
NADH levels using fluorescent spectroscopy of rat cardi-
ac trabeculae. They concluded that there was an equal
contribution of mechanical work and calcium cycling to
total ATP hydrolysis. In the present study, we hypothe-
sized that energy consumption during altered inotropy is
largely related calcium handling. To study this we direct-
ly measured developed pressures, myocardial oxygen
consumption and used a newly developed technique to
measure intracellular calcium in perfused mouse hearts
with the calcium sensitive fluorescent dye rhod-2 [6,7]
during calcium-induced inotropy and with dobutamine.
In addition we studied the perfused mouse heart, as the
ability to manipulate the murine genome will likely pro-
vide important information about the molecular deter-
minants of energy consumption in the heart.
The mechanisms controlling calcium-induced inotropy
are probably several fold, and include activation of pro-
tein kinase C [8], of which several isoforms are calcium
dependent. Protein kinase C decreases maximal actomy-
osin MgATPase activity through phosphorylation of tro-
ponin I [9]. This would be predicted to result in a
reduction in force (or developed pressure) relative to in-
tracellular calcium resulting in an energetically ineffi-
cient state. Thus, we predicted that high perfusate
calcium positive inotropy would result in lower devel-
oped pressures relative to both intracellular calcium and
myocardial oxygen consumption compared to dob-
utamine, and that high perfusate calcium would be asso-
ciated with evidence of protein kinase C activation,
though not dobutamine.
Results
During increases in perfusate calcium (1.5 – 3.5 mM)
there were stepwise increases in developed pressure, and
developed pressures with dobutamine were significantly
higher than perfusate calcium 3.5 mM (Figure 1A). Peak
systolic intracellular calcium increased minimally be-
tween 1.5 and 2.5 mM despite significant increases in de-
veloped pressures indicating increased myofilament
responsiveness to calcium at perfusate calcium 2.5 com-
pared to 1.5 mM (Figure 1B). Also, indicating reduced
myofilament responsiveness to perfusate calcium 3.5
mM compared to dobutamine, levels of peak intracellu-
lar calcium were similar for these 2 interventions despite
higher developed pressure with dobutamine. Increases
in myocardial oxygen consumption reflected the changes
in peak intracellular calcium, in that there were minimal
changes between 1.5 and 2.5 mM perfusate calcium, and
myocardial oxygen consumption was not significantly
different between perfusate calcium 3.5 mM and dob-
utamine (Figure 1C). Thus, the ratio of developed pres-
sure to myocardial oxygen consumption, an index of
economy of contraction, significantly increased between
1.5 and 2.5 mM perfusate calcium and was significantly
higher with dobutamine compared to high perfusate cal-
cium (Figure 1D).
To further explore the differences between dobutamine
and high calcium positive inotropy, analysis of pressure
and calcium transient waveforms and phase-plane plots
relating pressure to calcium was performed. Pressure
waveforms were significantly abbreviated with dob-
utamine compared to high perfusate calcium (total
waveform duration: 100 ± 15 vs 125 ± 0 ms, p < 0.01). The
time from onset of the pressure waveform to peak pres-
sure was not significantly different between dobutamine
and high calcium (45 ± 3 vs 52 ± 7 ms, p=NS), though the
time from peak pressure to fall to baseline was signifi-
cantly shorter with dobutamine compared to high calci-
um (55 ± 12 vs 73 ± 7 ms, p < 0.05). An example of a
normalized pressure waveform is shown in Figure 2. No
significant differences were seen with calcium transient
durations at any level of perfusate calcium or dob-
utamine (examples Figure 3A,B and 3C). Total transient
duration at 3.5 mM perfusate calcium was 106 ± 20 ms
and with dobutamine was 93 ± 22 ms (p=NS), and there
was also no significant difference in the time from onset
of the transient to peak (3.5 mM perfusate calcium 33 ±
8 vs dobutamine 38 ± 14 ms, p=NS), or difference in the
duration between the peak of the transient to return to
baseline (3.5 mM perfusate calcium 72 ± 25 vs dob-
utamine 60 ± 25 ms, p=NS). Phase-plane plots illustrate
that high perfusate calcium results in a similar increase
in intracellular calcium compared to dobutamine though
relatively smaller increase in pressure (Figure 3D,E, and
3F). Thus, the ratio of pressure to calcium at the point of
peak systolic pressure is significantly higher with dob-
utamine compared to high perfusate calcium (0.103 ±
0.009 vs 0.081 ± 0.012 mmHg/nM, p < 0.05, Figure 4).BMC Physiology 2001, 1:12 http://www.biomedcentral.com/1472-6793/1/12
The increase in the 'dynamic trajectory' of the phase-
plane plot between peak calcium and peak pressure may
relate to underlying changes in the steady-state force-
calcium relationship as proposed by Hunter [10].
The specific protein kinase C inhibitor chelerythrine sig-
nificantly inhibited high calcium positive inotropy (2.5 to
3.5 mM, p < 0.05), though had no effects on dobutamine,
or with lower levels of perfusate calcium (1.5 to 2.5 mM)
(Figure 5A). The effects of chelerythrine were mediated
through preventing the expected increase in systolic and
diastolic intracellular calcium (figure 5B). The difference
in myocardial oxygen consumption between 2.5 and 3.5
mM perfusate calcium was significantly reduced with the
addition of chelerythrine (∆  2.5 to 3.5 mM alone: 9.1 ±
2.8 vs ∆  2.5 to 3.5 mM + chelerythrine: 5.4 ± 1.2 µmoles/
min/g dry wt., p < 0.05). Also, chelerythrine had no sig-
nificant effects on developed pressures at a constant per-
fusate calcium of 2.5 mM (53 ± 9 to 50 ± 10 mmHg,
p=NS).
Discussion
In the present study we have directly related developed
pressures, myocardial oxygen consumption and intracel-
lular calcium in perfused mouse hearts. The results dem-
onstrate that there are significant differences between
high perfusate calcium and the predominant β -adrener-
gic agonist dobutamine in the perfused mouse heart.
High perfusate calcium results in less myofilament calci-
um responsiveness and reduced energetic efficiency
compared to dobutamine and also is dependent in part
on protein kinase C activation. There are also significant
differences in myofilament responses to calcium and en-
ergetic efficiency between different levels of perfusate
calcium. These data support the hypothesis that intracel-
lular calcium cycling is responsible for a significant pro-
portion of total myocardial oxygen consumption during
changes in inotropy [11], and thus alterations in myofila-
ment protein calcium responsiveness may result in a sig-
nificant effect on the energetic characteristics of a
particular inotrope.
Figure 1
A. Developed pressure at perfusate calcium 1.5 – 3.5 mM and with dobutamine (dob, 0.9 µM). B. Peak systolic intracellular cal-
cium, C. Myocardial oxygen consumption (MVO2), D. Ratio of developed pressure to myocardial oxygen consumption (DP/
MVO2). Symbols for Figure 1A: * p < 0.005 vs perfusate calcium 2.0, 2.5, 3.5 mM and dobutamine; † p < 0.05 vs dobutamine and
perfusate calcium 3.5 mM; §p < 0.0001 vs dobutamine; ** p < 0.05 vs dobutamineSymbols for Figure 1B:* p < 0.005 vs perfusate
calcium 3.5 mM and dobutamine; † p < 0.05 vs perfusate calcium 3.5 mM and dobutamine; Symbols for Figure 1C:† p = 0.05 vs
dobutamine; § p < 0.05 vs dobutamineSymbols for Figure 1D:* p < 0.0001 vs perfusate calcium 2.0, 2.5, 3.5 mM and dob-
utamine; † p < 0.0001 vs dobutamine; §p < 0.0005 vs dobutamine; ** p < 0.05 vs dobutamine
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Protein kinase C phosphorylation of troponin I (predom-
inantly at serines 43/45) results in a decrease in maximal
actin-myosin ATPase activity [9], and also a decrease in
the calcium sensitivity of the contractile apparatus
through cross-phosphorylation of protein kinase A sites
(serines 23/24) on troponin I [9]. Dobutamine, which is
predominantly a β -adrenergic agonist, activates protein
kinase A, which mediates a reduction in the calcium sen-
sitivity of the contractile apparatus through phosphor-
ylation of troponin I, though it does not effect maximal
actin-myosin ATPase activity [12]. The findings suggest-
ing that protein kinase C is activated at higher levels of
perfusate calcium (though not with dobutamine) may in-
dicate a role for protein kinase C in the energetic ineffi-
ciency associated with high calcium. That force does not
increase proportionate to the rise in intracellular calcium
during calcium-induced inotropy maybe related to 'down
stream' effects of protein kinase C, such as phosphoryla-
tion of troponin I reducing maximal actin-myosin AT-
Pase activity [9]. Indeed, recently we have shown that in
a transgenic mouse expressing mutant troponin I lacking
protein kinase C phosphorylation sites that during high
perfusate calcium inotropy that there is a significant ele-
vation in the ratio of developed pressure to myocardial
oxygen consumption relative to wild type controls [13].
This data together with the data in the present manu-
script provides reasonable evidence that activation of
protein kinase C during high calcium-induced inotropy
reduces maximal myofilament calcium responsiveness
resulting in a decrease in developed pressure relative to
peak systolic calcium, and energetic inefficiency. Also,
conditional expression of protein kinase C β  in mice [14],
which is well suited to study the immediate effects of pro-
tein kinase C activation, is associated with increased con-
tractility and calcium transients and decreased maximal
tension development by myofilaments when expression
Figure 2
Example of normalized pressure waveforms for dobutamine and 3.5 mM perfusate calcium, illustrating abbreviation of the dob-
utamine waveform compared to 3.5 mM perfusate calcium.BMC Physiology 2001, 1:12 http://www.biomedcentral.com/1472-6793/1/12
is turned on. This compares favorably with our data
showing that protein kinase C inhibition results in de-
creased contractility and reduced calcium transients.
The abbreviation of the pressure waveforms with dob-
utamine compared to high perfusate calcium is another
marked difference between these 2 forms of positive in-
otropy. Differences in phosphorylation of proteins in-
volved in relaxation such as troponin I and
phospholamban may account for this [15,16]. We have
not found any difference in the calcium transient dura-
tion to accompany the pressure waveform findings. This
may relate to the relatively limited number of sampling
points (N = 8) used in obtaining calcium transients or
motion artifact related to the inotropic state. Recent im-
provements in acquisition software and recording capa-
bilities will likely improve our ability to analyze calcium
transients in detail.
Measurement of intracellular calcium and myocardial ox-
ygen consumption in the perfused mouse heart
Isolated perfused mouse heart measurements of intrac-
ellular calcium and energetics have been performed us-
ing other methods by other investigators [17,18]. The
unique aspects of the present study are that we use the
calcium sensitive fluorescent dye rhod-2 to measure in-
tracellular calcium [6,7], and that we have related these
measurements to both myocardial oxygen consumption
and developed pressure. An appreciation of the strengths
and limitations of these techniques is required to critical-
ly evaluate the results. For instance, measurements of in-
tracellular calcium are taken from the outer layers of the
left ventricular free wall, though our measurements of
myocardial oxygen consumption and developed pres-
sures are global measurements. Differences between the
epicardium and endocardium have been described [19]
and our measurements of intracellular calcium do not
Figure 3
A: Averaged calcium transients (6–8 cycles) at perfusate calcium 1.5 and 2.5 mM, B: perfusate calcium 2.5 and 3.5. mM, and C:
perfusate calcium 2.0 mM and with dobutamine. D. Phase-plane plots of pressure and calcium at perfusate calcium 1.5 and 2.5
mM, E: perfusate calcium 2.5 and 3.5. mM, and F: perfusate calcium 2.0 mM and with dobutamine.BMC Physiology 2001, 1:12 http://www.biomedcentral.com/1472-6793/1/12
take this into account, and regional differences in myo-
cardial strains and oxygen consumption are also not ac-
counted for. However, one advantage of using rhod-2 is
that its long excitation and emission wavelengths rela-
tive to other calcium sensitive dyes results in minimal fil-
tering of excitation and emission light and
autofluorescence [7,20]. At these visible range wave-
lengths light may penetrate between 0.3 and 0.4 mm into
the myocardium [21] which may be significantly deeper
than shorter wavelength dyes. This is approximately
50% of the total wall thickness in the mouse [22], and
thus our measurements are from the outer 50% of the
myocardium.
Measurements of intracellular calcium and myocardial
oxygen consumption have been performed in different
hearts due to the difficulty in obtaining these measure-
ments in a single experiment, and this may introduce
variability into the results. We have also performed only
2 interventions per heart. The time taken to obtain stable
measurements of effluent oxygen saturations used in the
calculation of myocardial oxygen consumption is ap-
proximately 30 minutes and the mouse heart prepara-
tion is usually not stable beyond 80 minutes, so that only
2 interventions can be obtained. Furthermore, when
comparing different inotropes such as high calcium and
dobutamine, it is desirable not to use the same heart. As
we have postulated that different signaling pathways
may be activated by these inotropes, serially administer-
ing these to a single heart may result in persistent activa-
tion of a protein kinase even after washout of that agent.
Figure 4
Averaged phase-plane plots for high perfusate calcium and dobutamine. While the increase in intracellular calcium is similar for
both, at peak pressure the ratio of pressure to intracellular calcium is significantly higher with dobutamine (* p < 0.05).
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Figure 5
A. Effects of protein kinase C inhibitor (PKCi) chelerythrine on inotropic responses (developed pressure) of perfusate calcium
1.5 to 2.5 mM (left), 2.5 to 3.5 mM (middle), and dobutamine (right). B. Effects of PKCi with perfusate calcium 2.5 to 3.5 mM
(left) on peak systolic intracellular calcium, and basal diastolic calcium (right). Baseline controls values (perfusate calcium 1.5,
2.0 or 2.5 mM) for these experiments include those experiments with addition of chelerythrine to the higher perfusate calcium
or dobutamine after control measurements, combined also with those experiments without chelerythrine. * p < 0.05, and ** p
< 0.005.
Table 1: Additional functional data, not included in Figure 1.
Perfusate Ca2+ (mM): Dias. P Volume Flow Dry heart Diastolic
(mmHg) (µL) (mL/min) weight (g) [Ca2+]i (nM)
1.5 3 ± 21 9 . 9  ± 0.8 2.2 ±0.1 0.029 ± 0.002 353 ± 60*
2.0 3 ± 32 3 . 3  ± 1.9 2.0 ± 0.3* 0.029 ± 0.002 375 ± 17†
2.5 5 ± 42 0 . 2  ± 0.6 2.3 ± 0.2† 0.025 ± 0.002 346 ± 93*
3.5 4 ± 42 0 . 4  ± 0.9 2.1 ± 0.2 0.025 ± 0.001 532 ± 53
3.5+Chelerythrine 2 ± 12 0 . 7  ± 1.6 2.2 ± 0.4 0.027 ± 0.001 369 ± 46*
Dobutamine 3 ± 32 3 . 3  ± 1.9 1.8 ± 0.2 0.029 ± 0.002 587 ± 41
Symbols for coronary flow column: * p < 0.05 vs 2.5 mM; † p < 0.05 vs dobutamine Symbols for diastolic calcium column: * p < 0.005 vs perfusate 
calcium 3.5 mM and dobutamine; † p < 0.05 vs perfusate calcium 3.5 mM and dobutamine.
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Coronary flow does not increase with inotropes in this
study, though other studies with perfused mouse hearts
have shown an increase [23]. The reason for this is un-
clear, though oxygen delivery to the heart is not compro-
mised. We have the advantage with the use of the
absorbance spectrum between 500 and 600 nm, used in
the calculation of intracellular calcium, that this is also
sensitive to the presence of deoxy- or oxygenated my-
oglobin [7]. With our technique the myoglobin spectrum
is invariably consistent with full oxygenation and any
(rare) hearts that do not show this pattern are discarded.
By using physiological heart rates and temperatures we
have attempted to reproduce normal murine physiologi-
cal conditions. As the mouse heart has a negative force-
frequency response at physiological heart rates [24], de-
veloped pressures in our studies are lower than might be
expected with lower heart rates. Nevertheless, the devel-
oped pressures in this study are quite consistent with
other studies [17,24,25]. That pressures in perfused
mouse heart studies are generally low may relate to the
resistance of the murine myocardium to extracellular
calcium [26]. Diastolic calcium levels are relatively high
with this method especially with dobutamine or 3.5 mM
perfusate calcium (table 1). This appears at least in part
related to the limited sampling of 8 time points per beat
in the current paper, and may also relate to motion arti-
fact associated with the positive inotropes. These limita-
tions are especially prominent in the small and rapid
beating mouse heart. Recently, improved analogue to
digital capabilities and software acquisition has signifi-
cantly improved our ability to record many more time
points during the cardiac cycle, and with this we have
noted slightly higher differences between peak and di-
astolic calcium levels (MacGowan and Koretsky, unpub-
lished data). It appears unlikely that this is related to a
calcium overload state as diastolic pressures do not rise
with high perfusate calcium or dobutamine, and pres-
sure waveforms abbreviate with dobutamine.
Conclusions
In the perfused mouse heart, high perfusate calcium pos-
itive inotropy compared to dobutamine results in re-
duced myofilament calcium responsiveness, decreased
energetic efficiency and is dependent in part on protein
kinase C activation. It must be recognized that agents
that increase the amplitude of the calcium transient
through activation of protein kinase A, such as phos-
phodiesterase inhibitors are associated with adverse out-
comes in congestive heart failure patients [27], and so
our findings with dobutamine are unlikely to translate
into clinical benefit. Nevertheless, these results illustrate
the importance of calcium handling in the energetic effi-
ciency of an inotrope, and these methods will be useful in
studying genetically engineered mouse models with al-
tered myofilament calcium responsiveness.
Materials and methods
The isolated perfused mouse heart and myocardial oxygen 
consumption
Experiments were performed in 2 groups. In one group,
developed pressure and myocardial oxygen consumption
were measured in the perfused mouse heart. In another
group of perfused hearts intracellular calcium and devel-
oped pressure were measured. Male mice (129/SV ter
strain, mean weight 26.9 ± 2.6 g) were used. Anesthesia
was induced with 1.5 to 3.0 mg of intraperitoneal pento-
barbital sodium, and the animal was anticoagulated with
100 units of heparin. The heart was removed from the
chest and the aorta was cannulated with a 23 gauge nee-
dle. Retrograde coronary perfusion at a constant per-
fusion pressure of 55 mmHg with oxygenated modified
Krebs solution was started. The Kreb's solution consisted
of (mM): NaCl 112, KCl 4.7, MgSO4 1.2, Na-EDTA 0.5,
NaHCO3 28.0, Glucose 5.5, Pyruvate 5.0, CaCl2 2.5, 50
µM octanoate, and pH was adjusted to 7.4. For some
studies the concentration of calcium was varied to pro-
duce an inotropic effect. The concentration of NaCl was
adjusted accordingly for these experiments to maintain
osmolality. To eliminate the effects of cathecholamine
release by pacing esmolol (0.1 µM) (Du Pont, Wilming-
ton, DE) was added to the perfusate. The temperature of
the perfusate entering the heart was set at 37°C. Flow
was monitored with a glass flow meter. A rubber latex
balloon on the end of a plastic cannula, was inserted into
the left ventricle through an incision in the left atrium.
This was then connected to a Gould pressure recorder
(Gould, Cleveland, Ohio) for measurement of left ven-
tricular pressure. The left ventricular diastolic pressure
was set at 0 – 5 mm Hg using a micro-syringe. Hearts
were paced at 8 Hz which is the physiological heart rate
for the mouse, using a stimulator with one lead inserted
into the right ventricle and the other adjacent to the epi-
cardium. In the myocardial oxygen consumption experi-
ments, the perfused mouse heart was placed in a glass,
water jacketed chamber, which was sealed at the top.
Myocardial oxygen consumption was determined from
influent and effluent oxygen content (measured by blood
gas analyzer, ABL-30, Copenhagen, Denmark) and flow
rate.
Measurement of Intracellular Calcium
The methods used to measure intracellular calcium with
rhod-2 in perfused hearts have been previously exten-
sively described [6,7,20]. Rhod-2 (Molecular Probes,
OR, 100 µg) was dissolved with dimethylsulfoxide (DM-
SO, 4 µL) and dH2O (200 µL), and loaded through the
coronary perfusate. After the washout period serial
measurements of fluorescence alternating with absorb-
ance were taken. Fluorescence scans were taken at high
time resolution to allow quantification of changes in flu-
orescence during the cardiac cycle. Excitation at 524 nmBMC Physiology 2001, 1:12 http://www.biomedcentral.com/1472-6793/1/12
and emission at 589 nm was used for fluorescence meas-
urements.
Quantification of the relative amount of rhod-2 in the
heart using absorbance measurements, was done by tak-
ing the ratio of absorbance at 524 nm (rhod-2 sensitive)
to 589 nm (rhod-2 insensitive) which eliminated the ef-
fect of motion as both wavelengths would be equally af-
fected by motion, though only 524 reflected the
concentration of rhod-2 [7]. These wavelengths (524,
589 nm) were chosen as these were isosbestic points not
effected by changes in absorbance of myoglobin induced
by oxygen desaturation [7]. In solution maximal rhod-2
absorbance is at 554 nm. However, this wavelength is ef-
fected by changes in oxygen saturation, the relative ab-
sorbance compared to 524 nm is decreased due to inner
filter effects and it does not adequately correct for chang-
es in scattering [7]. Dye absorbance (Arhod2) was calcu-
lated according to the formula:
Arhod2 = log{(R524/R589)0/(R524/R589)rhod2}   (1)
where R524 is the reflectance intensity at the rhod-2 sen-
sitive point of 524 nm, and R589 is the rhod-2 insensitive
point, before ()0 and after ()rhod2 loading.
At the end of the perfusion protocol, maximal fluores-
cence, used in the calculation of [Ca2+]i was determined
by tetanizing the heart with a bolus of calcium chloride
(20 mM) without any energy substrate, and with cyclopi-
azonic acid (Sigma Chemical Co., 10 µM), which is a po-
tent inhibitor of Ca2+-ATPase and thus blocks calcium
uptake by the sarcoplasmic reticulum [28]. Fluorescence
and pressure were monitored continuously, and the
point of maximal fluorescence was taken as the point
were pressure stabilized at a steady state. To account for
changes in light scattering properties from the heart dur-
ing tetanization, the maximal fluorescence was corrected
by multiplying by the ratio of R524 pre-tetanization to
R524 during tetanization [7].
Intracellular calcium was calculated using the formula:
[Ca2+]i = Kd(Ft - Fo)/(Fmax - Ft)   (2)
where Kd is the dissociation constant for rhod-2 and cal-
cium (determined by in-vitro calibration with rhod-2
and myoglobin by del Nido et al, ref [20], and confirmed
by in-vivo manganese quenching, ref [29]) and is 710
nM, Ft = fluorescence at time t, Fmax =maximal fluores-
cence from tetanized heart, and the fluorescence from
the heart assuming rhod-2 had no calcium bound is giv-
en by F0 = Fb + a(Fmaxt - Fb), where Fb is the background
counts from the heart prior to dye loading, and a = rhod-
2 fluorescence in the absence of calcium / rhod-2 fluores-
cence in the presence of saturating calcium. For rhod-2
the value of a is approximately 0, thus for rhod-2, F0 was
assumed to be equal to Fb.
To account for changes in dye concentration, formula 2
needs to be modified to account for changes in absorb-
ance (Arhod-2, formula 1) due to dye leakage.
[Ca2+]i = Kd((Ft - Fo)/At)/(((Fmax - Fo)/Amax) - ((Ft -
Fo)/At))   (3)
where At = dye absorbance at time t, Amax is dye absorb-
ance just prior to tetanizing the heart. Amax is not deter-
mined when heart has tetanized because of the marked
influence of the shape change and desaturation of my-
oglobin on the reflectance spectrum.
Interventions
For each heart only a baseline and one intervention was
used, and N = 4–6 for all groups. The time to achieve a
stable state (particularly with respect to effluent PO2
concentrations) or load rhod-2, and then acquire base-
line data and perform 1 intervention is 60–90 minutes,
beyond which the preparation is not stable and so more
than 1 intervention per mouse heart was not undertaken.
In the developed pressure/oxygen consumption experi-
ments, the following interventions were used: 1) varying
perfusate calcium from baseline 2.5 mM to 3.5; 2) base-
line perfusate calcium 1.5 mM to 2.5 mM; 3) baseline
perfusate calcium 2.0 mM and then addition of dob-
utamine 0.9 µM.; 4) to antagonize the effects of protein
kinase C, the specific antagonist chelerythrine (ref 30; 10
nM, Calbiochem-Novabiochem Intl, La Jolla, CA) was
added to the perfusate when inducing positive inotropy.
In all of these the chelerythrine was added to the per-
fusate containing the higher level of perfusate calcium or
dobutamine. This dose was chosen to reduce the expect-
ed increase in pressure with perfusate calcium 3.5 mM
by 50% after dose ranging studies (1 nM to 1000 nM). In
addition in another group of experiments during con-
stant infusion of perfusate calcium 2.5 mM, cheleryth-
rine was added without changing perfusate calcium
concentration. In all experiments, the control period was
followed by the intervention, and repeated measure-
ments of both developed pressure and myocardial oxy-
gen consumption were taken for a period of
approximately 30 minutes. Measurements of intracellu-
lar calcium were performed 1) at perfusate calcium con-
centrations at baseline of 2.5 mM increasing to 3.5 mM,
2) decreasing from 2.5 to 1.5 mM, and 3) 2.0 mM base-
line with subsequent addition of dobutamine 0.9 µM.
The effects of chelerythrine on intracellular calcium was
only determined for those interventions with which chel-
erythrine had significant effects on myocardial oxygen
consumption and developed pressure.BMC Physiology 2001, 1:12 http://www.biomedcentral.com/1472-6793/1/12
Data and Statistical Analysis
One way analysis of variance with the Scheffe test was
used to test significance of differences between groups.
Developed pressure data from the myocardial oxygen
consumption and intracellular calcium experiments
were combined as this was obtained under the same ex-
perimental conditions. The ratio of developed pressure
to myocardial oxygen consumption was derived as an in-
dex of economy of contraction. Data are expressed as
mean ± standard deviation.
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